Inventor · disambiguated record
Alexandre Cote
Also filed as: COTE ALEXANDRE · CÔTÉ ALEXANDRE
37 granted patents·12 pending applications·244 citations·filing 2001–2024
97Inventor score
Files withGENENTECH INC15NIMBUS SATURN INC10CONSTELLATION PHARMACEUTICALS INC8PHARMACOR INC5VENTUS THERAPEUTICS U S INC5
Top patents by PatentIndex Score
49 records- 0197US11034694B2Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonistsNIMBUS SATURN INC·Filed 2020·Granted Jun 15, 2021·12 cites·22 claims
- 0297US9249161B2Bromodomain inhibitors and uses thereofALBRECHT BRIAN K·Filed 2011·Granted Feb 2, 2016·50 cites·12 claims
- 0396US11078201B2Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonistsNIMBUS SATURN INC·Filed 2020·Granted Aug 3, 2021·7 cites·22 claims
- 0496US11028085B2Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonistsNIMBUS SATURN INC·Filed 2020·Granted Jun 8, 2021·6 cites·22 claims
- 0596US11021481B2Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonistsNIMBUS SATURN INC·Filed 2020·Granted Jun 1, 2021·7 cites·22 claims
- 0695US11548890B1HPK1 antagonists and uses thereofNIMBUS SATURN INC·Filed 2021·Granted Jan 10, 2023·3 cites·30 claims
- 0792US9763922B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2015·Granted Sep 19, 2017·9 cites·20 claims
- 0892US8796261B2Bromodomain inhibitors and uses thereofALBRECHT BRIAN K·Filed 2011·Granted Aug 5, 2014·21 cites·28 claims
- 0990US10689371B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2019·Granted Jun 23, 2020·5 cites·29 claims
- 1090US9328117B2Bromodomain inhibitors and uses thereofALBRECHT BRIAN K·Filed 2012·Granted May 3, 2016·8 cites·15 claims
- 1190US6506786B2HIV protease inhibitors based on amino acid derivativesPHARMACOR INC·Filed 2001·Granted Jan 14, 2003·20 cites·17 claims
- 1288US11274095B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2020·Granted Mar 15, 2022·2 cites·34 claims
- 1387US10308614B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Jun 4, 2019·4 cites·21 claims
- 1487US9745305B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2014·Granted Aug 29, 2017·11 cites·17 claims
- 1587US9522920B2Bromodomain inhibitors and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2014·Granted Dec 20, 2016·10 cites·21 claims
- 1687US6677367B2HIV protease inhibitors based on amino acid derivativesPHARMACOR INC·Filed 2002·Granted Jan 13, 2004·14 cites·6 claims
- 1787US2025250270A1Compounds for inhibiting nlrp3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2024·Application pending·0 cites
- 1886US12410167B2Pyridazine compounds for inhibiting NLRP3VENTUS THERAPEUTICS U S INC·Filed 2023·Granted Sep 9, 2025·0 cites·17 claims
- 1986US6656965B2HIV protease inhibitors based on amino acid derivativesPHARMACOR INC·Filed 2002·Granted Dec 2, 2003·12 cites·4 claims
- 2086US6610689B2HIV protease inhibitors based on amino acid derivativesPHARMACOR INC·Filed 2002·Granted Aug 26, 2003·14 cites·22 claims
- 2185US2024158396A1Compounds for inhibiting nlrp3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2023·Application pending·0 cites
- 2283US10206931B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Feb 19, 2019·5 cites·17 claims
- 2383US2024025898A1Hpk1 antagonists and uses thereofNIMBUS SATURN INC·Filed 2023·Application pending·0 cites
- 2482US11919912B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2019·Granted Mar 5, 2024·2 cites·18 claims
- 2582US6608100B1HIV protease inhibitors based on amino acid derivativesPHARMACOR INC·Filed 2002·Granted Aug 19, 2003·14 cites·10 claims
- 2680US10526287B2LSD1 inhibitors and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2016·Granted Jan 7, 2020·2 cites·22 claims
- 2779US10183009B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Jan 22, 2019·3 cites·22 claims
- 2878US10239861B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Mar 26, 2019·2 cites·7 claims
- 2977US2022340567A1Compounds for inhibiting nlrp3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2022·Application pending·0 cites
- 3075US12466841B2Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonistsNIMBUS SATURN INC·Filed 2023·Granted Nov 11, 2025·0 cites·24 claims
- 3174US2024116905A1Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3272US12215105B2HPK1 antagonists and uses thereofNIMBUS SATURN INC·Filed 2020·Granted Feb 4, 2025·0 cites·18 claims
- 3368US10150767B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Dec 11, 2018·1 cites·14 claims
- 3466US12071442B2Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonistsNIMBUS SATURN INC·Filed 2022·Granted Aug 27, 2024·0 cites·19 claims
- 3565US2024368131A1Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereofVENTUS THERAPEUTICS U S INC·Filed 2024·Application pending·0 cites
- 3660US2025011331A1Hpk1 antagonists and uses thereofNIMBUS SATURN INC·Filed 2022·Application pending·0 cites
- 3756US2024158412A1Ubiquitin-specific protease 7 (usp7) inhibitors and uses thereofFAXIAN THERAPEUTICS LLC·Filed 2022·Application pending·0 cites
- 3855US2017333406A1Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Application pending·0 cites
- 3953US11459315B2Modulators of methyl modifying enzymes, compositions and uses thereofCONSTELLATION PHARMACEUTICALS INC·Filed 2018·Granted Oct 4, 2022·0 cites·11 claims
- 4051US2024018102A1Compounds and compositions for treating conditions associated with lpa receptor activityLHOTSE BIO INC·Filed 2021·Application pending·0 cites
- 4147US10358437B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Jul 23, 2019·0 cites·9 claims
- 4241US10301253B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted May 28, 2019·0 cites·21 claims
- 4341US2016024504A1Treating th2-mediated diseases by inhibition of bromodomainsGENENTECH INC·Filed 2014·Application pending·0 cites
- 4440US10280149B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted May 7, 2019·0 cites·21 claims
- 4540US10258603B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Apr 16, 2019·0 cites·15 claims
- 4640US10202354B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Feb 12, 2019·0 cites·16 claims
- 4740US8492574B2Methods for preparing dioranozinc compoundsCHARETTE ANDRE·Filed 2009·Granted Jul 23, 2013·0 cites·75 claims
- 4838US10155764B2Therapeutic compounds and uses thereofGENENTECH INC·Filed 2017·Granted Dec 18, 2018·0 cites·23 claims
- 4936US2016317632A1Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapyGENENTECH INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alexandre Cote files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →